“The new Seeplex STD/HPV diagnostic test enables healthcare providers to quickly, accurately, and cost-effectively determine most prevalent STD/HPV infections in patients,” the company claimed.
Seegene launched this week a new Seeplex STD/HPV Test that detects Chlamydia trachomatis, Neisseria gonorrhea, as well as 14 high-risk and five low-risk human papillomaviruses in a single tube.
The company introduced this test “in an effort to encourage widespread STD screening to help slow the transmission of these infections and promote more responsive and effective patient care.”
Seegene said that current clinical STD and HPV screening procedures are not cost-efficient because a separate test is required for each indication. The company said that the cost to patients to get tested for all the indications on the Seeplex STD/HPV test will be $20.